Novel fluorescent probes with improved stability and affinity for Gai1 protein

The Gai1 protein subunit can function as an essential molecular switches for the GPCR-mediated intracellular signaling by switching between the GDP-bound (inactive) and the GTP-bound state (active). [1] Dysregulation of the switching mechanism is associated with diverse pathophysiologies, such as heart failure, cancer etc., making Gai proteins attractive therapeutic targets in drug research. [2] Various approaches have been described in the past using fluorescent GTP analogs targeting the Gai1 proteins, lacking thogh both the accurate determination of the protein's guanine nucleotide binding affinity and the quantification of the active protein fraction. [3] Pepanian et al. recently developed a fluorescence anisotropy (FA)-based method to determine the binding affinity at the GTP-binding site and quantify the Gai1 protein activity. [3] Since commonly used MANT-and BODIPY- [4-6] based probes lack broad applicability for FA-based assays, a new generation of fluorescein (FAM) labeled GTP analogs was developed with beneficial properties for FA-assay including high quantum yields and relatively short fluorescence lifetimes of the excited state (3.8 ns). [3] Two y-[(4-Aminobutyl)triazolo]-GTP-5-FAM high-affinity probes y-[(6and Aminohexyl)triazolo]-GTP-5-FAM for Gai1 (K_D values in the one-digit nM range) have been identified that possess an improved hydrolytic stability and binding affinity compared to MANT GTPyS and BODIPY FL GTPyS. [3]



Figure 1. 5-FAM labeled GTP analogs with improved stability and affinity for the G α i1 protein compared to BODIPY FL GTP γ S.

A) Chemical structures of <u>y-[(4-Aminobutyl)triazolo]-GTP-5-FAM (NU-1219-5FM)</u>, <u>y-[(6-Aminohexyl)triazolo]-GTP-5-FAM (NU-1220-5FM) and GTPyS-BDP-FL (NU-973)</u>.
B) Assay ashama for determination of binding affinity of the fluorescent CTP analogs via fluorescence.

B) Assay scheme for determination of binding affinity of the fluorescent GTP analogs via fluorescence anisotropy-based method. (Figure adapted from Pepanian *et al.* [3])

C) Dissociation constants (K_D) of <u>y-[(4-Aminobutyl)triazolo]-GTP-5-FAM (NU-1219-5FM)</u>, <u>y-[(6-Aminohexyl)triazolo]-GTP-5-FAM (NU-1220-5FM)</u> and GTPγS-BDP-FL (NU-973) on Gαi1 protein. [3]

Table 1: Available Gαi1-specific probes developed by Pepanian *et al.* [3].

Cat. No.	Product Name	Specifications
NU-1219-5FM	<u>y-[(4-Aminobutyl)triazolo]-GTP-5-FAM</u>	Purity: >/= 95 % (HPLC) Concentration: 1.0 mM – 1.1 mM pH: 7.5 ±0.5
NU-1220-5FM	y-[(6-Aminohexyll)triazolo]-GTP-5-FAM	Purity: >/= 95 % (HPLC) Concentration: 1.0 mM – 1.1 mM pH: 7.5 ±0.5

Selected References:

[1] Nubbemeyer *et al.* (2021) Strategies towards targeting Galpha(i/s) proteins: Scanning of protein-protein interaction sites to overcome inaccessibility. *ChemMedChem.* 15: 1696-1715. DOI: 10.1002/cmdc.202100039.

[2] O'Hayre *et al.* (2013) The emerging mutational landscape of G proteins and G-proteincoupled receptors in cancer. *Nat Rev Cancer.* 13:412-24.

[3] Pepanian *et al.* (2022) Fluorescence Anisotropy Assay with Guanine Nucleotides Provides Access to Functional Analysis of Gai1 Proteins. *Anal Chem.* **94**:14410-14418.

[4] Gille *et al.* (2003) 2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. *J Biol Chem.* **278**:12672-9.

[5] McEwen *et al.* (2001) Fluorescent BODIPY-GTP analogs: real-time measurement of nucleotide binding to G proteins. *Anal Biochem.* **291**:109-17.

[6] Gille *et al.* (2003) Low-affinity interactions of BODIPY-FL-GTPgammaS and BODIPY-FL-GppNHp with G(i)- and G(s)-proteins. *Naunyn Schmiedebergs Arch. Pharmacol.* **368**:210.